Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2013

View Archived Issues

Pfizer's IMA-638 does not meet endpoints in phase IIa trial

Updated immunological results published from phase I evaluation of AE37 prostate cancer vaccine

Antibody DCBPR-01101 targets globo H for breast cancer treatment

Immunology data reported from phase IIb AllerT vaccine birch pollen allergy study

FDA approves subcutaneous formulation of Actemra for rheumatoid arthritis

Oxygen Biotherapeutics to complete development of levosimendan for fast track indication

AstraZeneca commences phase III program for selumetinib in NSCLC

Shionogi & Co. patents novel TRPV4 antagonists for pain

New EGFR inhibitors divulged by Chinese researchers

R-Pharm CJSC prepares new fusion proteins that bind to RANKL

Polaris submits IND application to begin phase I trials of ADI-PEG-20 in breast cancer

Novel coagulation factor Xa inhibitors synthesized at SciFluor Life Sciences

TherapeuticsMD's TX-12-004-HR estradiol VagiCap shown to improve objective measures of VVA

FDA grants orphan drug designation to Aduro's immunotherapy for pancreatic cancer

Phase I study evaluates Debio-0932 plus everolimus for advanced RCC

New model of Parkinson's disease created with proteasome inhibitor injection

Chemilia presents a new microtubule targeting/vascular disrupting agent

AstraZeneca to begin phase I study of AZD-6738

New PARP6 inhibitors identified for ovarian and breast cancer

Medivation and Astellas' phase III trial of enzalutamide in prostate cancer meets primary endpoints

Ferring initiates two phase III trials of infertility treatment candidate FE-999049

Amgen acquires Roche's rights to filgrastim and pegfilgrastim

Biocartis licenses test for colon cancer biomarker from Hospital del Mar

Cubist files NDA for tedizolid for treatment of serious skin infections

European approval of Gentium's Defitelio for severe veno-occlusive disease

Thomson Reuters and Orion Bionetworks to develop predictive models for multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...